Press-release for stocks related to genetown for sny

tags : Genetown symbols : Sny

save search

Orna Therapeutics Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -1.64% | O: -100.0% H: NaN% C: Infinity%
VSTM | $9.695 -1.47% -1.5% 95K

Health Technology

| -13.92% | O: -0.4% H: 4.84% C: 4.79%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -2.33% | O: 0.05% H: 0.0% C: 0.0%
medical therapeutics

BPGbio Presents Key Advances in its Oncology Pipeline related to the NAi Interrogative Biology Platform
Published: 2024-04-05 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -3.54% | O: -1.77% H: 0.0% C: -1.81%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -4.77% | O: -3.44% H: 0.0% C: 0.0%
pipeline key platform

Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Published: 2024-03-27 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -7.26% | O: -0.26% H: 0.0% C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -5.95% | O: 1.06% H: 0.0% C: 0.0%
MRNA | News S | $104.48 3.03% 2.94% 3.1M

Health Technology

| -2.75% | O: 2.02% H: 1.41% C: 0.92%
vaccine trials

GRO Biosciences Expands Executive Team with Appointment of Biopharma Veteran Tracey Lodie, PhD as Chief Development Officer
Published: 2024-03-18 (Crawled : 12:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -4.43% | O: -0.81% H: 0.0% C: 0.0%
biopharma

Valo Health Completes Enrollment of OPL-0401 Phase 2 Study for the Treatment of Diabetic Retinopathy
Published: 2024-03-04 (Crawled : 18:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -1.9% | O: -0.9% H: 0.0% C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -2.33% | O: -0.8% H: 0.0% C: 0.0%
opl-0401 health treatment study diabetic

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
Published: 2024-02-15 (Crawled : 14:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| 2.49% | O: 1.16% H: 1.48% C: 0.89%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| 1.35% | O: 1.86% H: 0.0% C: 0.0%
ALNY | $145.78 0.95% 0.94% 390K

Health Technology

| -11.18% | O: -8.62% H: 2.18% C: -1.71%
year pharmaceuticals financial results

Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
Published: 2023-12-13 (Crawled : 14:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -1.13% | O: -0.06% H: 2.36% C: 2.36%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -2.39% | O: -0.27% H: 2.28% C: 2.16%
ALNY | $145.78 0.95% 0.94% 390K

Health Technology

| -16.15% | O: -0.14% H: 4.22% C: 3.97%
day innovation pipeline platform

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474
Published: 2023-10-27 (Crawled : 12:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -11.93% | O: -18.18% H: 0.0% C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -12.92% | O: -15.73% H: 0.0% C: 0.0%
KYMR | $34.37 1.18% 1.16% 420K

Health Technology

| 198.44% | O: 0.78% H: 0.0% C: -5.43%
kt-474 trial therapeutics phase 2

Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine
Published: 2023-10-25 (Crawled : 23:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -10.43% | O: 0.4% H: 1.29% C: 1.29%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -11.67% | O: 1.43% H: 0.64% C: -0.09%
ALNY | $145.78 0.95% 0.94% 390K

Health Technology

| -11.08% | O: -1.28% H: 0.58% C: -1.46%
publication results study

Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-10-25 (Crawled : 19:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -10.43% | O: 0.4% H: 1.29% C: 1.29%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -11.67% | O: 1.43% H: 0.64% C: -0.09%
ALNY | $145.78 0.95% 0.94% 390K

Health Technology

| -11.08% | O: -1.28% H: 0.58% C: -1.46%
disease alzheimer’s positive results

Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-10-09 (Crawled : 14:30) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -14.1% | O: 0.19% H: 0.0% C: 0.0%
ALNY | $145.78 0.95% 0.94% 390K

Health Technology

| -17.6% | O: -4.06% H: 2.17% C: -0.83%
fda drug treatment application response

RoslinCT Boston Appoints Dean J. Morris, as Chief Operations Officer
Published: 2023-10-03 (Crawled : 13:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -14.4% | O: -1.41% H: 0.0% C: 0.0%